JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB314623

Recombinant Human OPRM1 Protein (His Tag)

Be the first to review this product! Submit a review

|

(0 Publication)

Recombinant Human OPRM1 Protein (His Tag) is a Human Full Length protein, in the 1 to 400 aa range, expressed in Escherichia coli, with >85%, suitable for SDS-PAGE.

View Alternative Names

MOR1, OPRM1, Mu-type opioid receptor, M-OR-1, MOR-1, Mu opiate receptor, Mu opioid receptor, MOP, hMOP

1 Images
SDS-PAGE - Recombinant Human OPRM1 Protein (His Tag) (AB314623)
  • SDS-PAGE

Supplier Data

SDS-PAGE - Recombinant Human OPRM1 Protein (His Tag) (AB314623)

(Tris-Glycine gel) Discontinuous SDS-PAGE (reduced) with 5% enrichment gel and 15% separation gel. The difference between the theoretical value and the observed value may be related to the molecular structure of the protein. The isoelectric point (PI) : 8.62, and the molecular weight of the basic protein is relatively small. At the same time, it is speculated that the protein may form a dimer, resulting in the appearance of high molecular weight bands. Observed band size : Monomer:43 kDa Dimer:90 kDa

Key facts

Purity

>85% SDS-PAGE

Expression system

Escherichia coli

Tags

10x His tag N-Terminus

Applications

SDS-PAGE

applications

Biologically active

No

Accession

P35372

Animal free

Yes

Carrier free

No

Species

Human

Reconstitution

We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Please reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg/mL. We recommend to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C/-80°C. Our default final concentration of glycerol is 50%.

Storage buffer

pH: 7.4 - 8 Constituents: 6% Trehalose, 0.87% Sodium chloride, 0.24% Tris, 0.05% 2-Octadecoxyethanol

storage-buffer

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Reactivity", "Dilution Info", "Notes"] }, "values": { "SDS-PAGE": { "reactivity":"TESTED_AND_REACTS", "dilution-info":"", "notes":"<p></p>" } } }

Sequence info

[{"sequence":"MDSSAAPTNASNCTDALAYSSCSPAPSPGSWVNLSHLDGNLSDPCGPNRTDLGGRDSLCPPTGSPSMITAITIMALYSIVCVVGLFGNFLVMYVIVRYTKMKTATNIYIFNLALADALATSTLPFQSVNYLMGTWPFGTILCKIVISIDYYNMFTSIFTLCTMSVDRYIAVCHPVKALDFRTPRNAKIINVCNWILSSAIGLPVMFMATTKYRQGSIDCTLTFSHPTWYWENLLKICVFIFAFIMPVLIITVCYGLMILRLKSVRMLSGSKEKDRNLRRITRMVLVVVAVFIVCWTPIHIYVIIKALVTIPETTFQTVSWHFCIALGYTNSCLNPVLYAFLDENFKRCFREFCIPTSSNIEQQNSTRIRQNTRDHPSTANTVDRTNHQLENLEAETAPLP","proteinLength":"Full Length","predictedMolecularWeight":null,"actualMolecularWeight":"47.6 kDa","aminoAcidEnd":400,"aminoAcidStart":1,"nature":"Recombinant","expressionSystem":"Escherichia coli","accessionNumber":"P35372","tags":[{"tag":"10x His","terminus":"N-Terminus"}]}]

Properties and storage information

Shipped at conditions
Blue Ice
Appropriate short-term storage duration
1-2 weeks
Appropriate short-term storage conditions
+4°C
Appropriate long-term storage conditions
-80°C
Aliquoting information
Add glycerol to a final volume of 50% for extra stability and aliquot
Storage information
The product can be stored for up to 12 months
False

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

The Mu Opioid Receptor also known as MOR mu receptor or mu opiate receptor represents an important protein involved in pain and reward mechanisms. It is a G-protein coupled receptor with a mass of approximately 45 kDa. This receptor shows broad expression in the central nervous system with significant presence in areas such as the brainstem thalamus and spinal cord. MORs have a high affinity for endogenous opioids such as endorphins as well as exogenous opioid drugs like morphine.
Biological function summary

The Mu Opioid Receptor plays an essential role in modulating pain perception and response to opioids. It interacts predominantly with inhibitory G-proteins reducing neuronal excitability by decreasing cAMP levels and increasing potassium ion conductance. MORs are part of opioid receptor family which also includes delta and kappa receptors forming a complex regulatory system for the opioid signaling pathways. These receptors also modulate the release of neurotransmitters like GABA and dopamine.

Pathways

Signaling through the Mu Opioid Receptor integrates with the analgesic and reward pathways. It is important in the pain modulation pathway where it influences the perception of and response to pain stimuli. MORs interact with proteins such as adenylate cyclase and beta-arrestin which mediate desensitization and down-regulation processes. This interaction can also modulate the activity of dopamine pathways further linking MOR to reward and addiction mechanisms.

The Mu Opioid Receptor is closely connected to conditions like addiction and chronic pain. Anomalies in MOR function or expression can lead to an increased risk of opioid addiction due to its pivotal role in the reward pathway. Additionally chronic pain conditions might involve altered MOR signaling or density impacting pain management. Understanding MOR interactions with proteins like dopamine receptors can provide deeper insights into Huntington’s disease and the role of opioid receptors in its pathology.

Specifications

Form

Lyophilized

General info

Function

Receptor for endogenous opioids such as beta-endorphin and endomorphin (PubMed : 10529478, PubMed : 12589820, PubMed : 7891175, PubMed : 7905839, PubMed : 7957926, PubMed : 9689128). Receptor for natural and synthetic opioids including morphine, heroin, DAMGO, fentanyl, etorphine, buprenorphin and methadone (PubMed : 10529478, PubMed : 10836142, PubMed : 12589820, PubMed : 19300905, PubMed : 7891175, PubMed : 7905839, PubMed : 7957926, PubMed : 9689128). Also activated by enkephalin peptides, such as Met-enkephalin or Met-enkephalin-Arg-Phe, with higher affinity for Met-enkephalin-Arg-Phe (By similarity). Agonist binding to the receptor induces coupling to an inactive GDP-bound heterotrimeric G-protein complex and subsequent exchange of GDP for GTP in the G-protein alpha subunit leading to dissociation of the G-protein complex with the free GTP-bound G-protein alpha and the G-protein beta-gamma dimer activating downstream cellular effectors (PubMed : 7905839). The agonist- and cell type-specific activity is predominantly coupled to pertussis toxin-sensitive G(i) and G(o) G alpha proteins, GNAI1, GNAI2, GNAI3 and GNAO1 isoforms Alpha-1 and Alpha-2, and to a lesser extent to pertussis toxin-insensitive G alpha proteins GNAZ and GNA15 (PubMed : 12068084). They mediate an array of downstream cellular responses, including inhibition of adenylate cyclase activity and both N-type and L-type calcium channels, activation of inward rectifying potassium channels, mitogen-activated protein kinase (MAPK), phospholipase C (PLC), phosphoinositide/protein kinase (PKC), phosphoinositide 3-kinase (PI3K) and regulation of NF-kappa-B (By similarity). Also couples to adenylate cyclase stimulatory G alpha proteins (By similarity). The selective temporal coupling to G-proteins and subsequent signaling can be regulated by RGSZ proteins, such as RGS9, RGS17 and RGS4 (By similarity). Phosphorylation by members of the GPRK subfamily of Ser/Thr protein kinases and association with beta-arrestins is involved in short-term receptor desensitization (By similarity). Beta-arrestins associate with the GPRK-phosphorylated receptor and uncouple it from the G-protein thus terminating signal transduction (By similarity). The phosphorylated receptor is internalized through endocytosis via clathrin-coated pits which involves beta-arrestins (By similarity). The activation of the ERK pathway occurs either in a G-protein-dependent or a beta-arrestin-dependent manner and is regulated by agonist-specific receptor phosphorylation (By similarity). Acts as a class A G-protein coupled receptor (GPCR) which dissociates from beta-arrestin at or near the plasma membrane and undergoes rapid recycling (By similarity). Receptor down-regulation pathways are varying with the agonist and occur dependent or independent of G-protein coupling (By similarity). Endogenous ligands induce rapid desensitization, endocytosis and recycling (By similarity). Heterooligomerization with other GPCRs can modulate agonist binding, signaling and trafficking properties (By similarity).. Isoform 12. Couples to GNAS and is proposed to be involved in excitatory effects.. Isoform 16. Does not bind agonists but may act through oligomerization with binding-competent OPRM1 isoforms and reduce their ligand binding activity.. Isoform 17. Does not bind agonists but may act through oligomerization with binding-competent OPRM1 isoforms and reduce their ligand binding activity.

Sequence similarities

Belongs to the G-protein coupled receptor 1 family.

Post-translational modifications

Phosphorylated. Differentially phosphorylated in basal and agonist-induced conditions. Agonist-mediated phosphorylation modulates receptor internalization. Phosphorylated by GRK2 in a agonist-dependent manner. Phosphorylation at Tyr-168 requires receptor activation, is dependent on non-receptor protein tyrosine kinase Src and results in a decrease in agonist efficacy by reducing G-protein coupling efficiency. Phosphorylated on tyrosine residues; the phosphorylation is involved in agonist-induced G-protein-independent receptor down-regulation. Phosphorylation at Ser-377 is involved in G-protein-dependent but not beta-arrestin-dependent activation of the ERK pathway (By similarity).. Ubiquitinated. A basal ubiquitination seems not to be related to degradation. Ubiquitination is increased upon formation of OPRM1:OPRD1 oligomers leading to proteasomal degradation; the ubiquitination is diminished by RTP4.

Subcellular localisation

Endosome

Product protocols

Target data

Receptor for endogenous opioids such as beta-endorphin and endomorphin (PubMed : 10529478, PubMed : 12589820, PubMed : 7891175, PubMed : 7905839, PubMed : 7957926, PubMed : 9689128). Receptor for natural and synthetic opioids including morphine, heroin, DAMGO, fentanyl, etorphine, buprenorphin and methadone (PubMed : 10529478, PubMed : 10836142, PubMed : 12589820, PubMed : 19300905, PubMed : 7891175, PubMed : 7905839, PubMed : 7957926, PubMed : 9689128). Also activated by enkephalin peptides, such as Met-enkephalin or Met-enkephalin-Arg-Phe, with higher affinity for Met-enkephalin-Arg-Phe (By similarity). Agonist binding to the receptor induces coupling to an inactive GDP-bound heterotrimeric G-protein complex and subsequent exchange of GDP for GTP in the G-protein alpha subunit leading to dissociation of the G-protein complex with the free GTP-bound G-protein alpha and the G-protein beta-gamma dimer activating downstream cellular effectors (PubMed : 7905839). The agonist- and cell type-specific activity is predominantly coupled to pertussis toxin-sensitive G(i) and G(o) G alpha proteins, GNAI1, GNAI2, GNAI3 and GNAO1 isoforms Alpha-1 and Alpha-2, and to a lesser extent to pertussis toxin-insensitive G alpha proteins GNAZ and GNA15 (PubMed : 12068084). They mediate an array of downstream cellular responses, including inhibition of adenylate cyclase activity and both N-type and L-type calcium channels, activation of inward rectifying potassium channels, mitogen-activated protein kinase (MAPK), phospholipase C (PLC), phosphoinositide/protein kinase (PKC), phosphoinositide 3-kinase (PI3K) and regulation of NF-kappa-B (By similarity). Also couples to adenylate cyclase stimulatory G alpha proteins (By similarity). The selective temporal coupling to G-proteins and subsequent signaling can be regulated by RGSZ proteins, such as RGS9, RGS17 and RGS4 (By similarity). Phosphorylation by members of the GPRK subfamily of Ser/Thr protein kinases and association with beta-arrestins is involved in short-term receptor desensitization (By similarity). Beta-arrestins associate with the GPRK-phosphorylated receptor and uncouple it from the G-protein thus terminating signal transduction (By similarity). The phosphorylated receptor is internalized through endocytosis via clathrin-coated pits which involves beta-arrestins (By similarity). The activation of the ERK pathway occurs either in a G-protein-dependent or a beta-arrestin-dependent manner and is regulated by agonist-specific receptor phosphorylation (By similarity). Acts as a class A G-protein coupled receptor (GPCR) which dissociates from beta-arrestin at or near the plasma membrane and undergoes rapid recycling (By similarity). Receptor down-regulation pathways are varying with the agonist and occur dependent or independent of G-protein coupling (By similarity). Endogenous ligands induce rapid desensitization, endocytosis and recycling (By similarity). Heterooligomerization with other GPCRs can modulate agonist binding, signaling and trafficking properties (By similarity).. Isoform 12. Couples to GNAS and is proposed to be involved in excitatory effects.. Isoform 16. Does not bind agonists but may act through oligomerization with binding-competent OPRM1 isoforms and reduce their ligand binding activity.. Isoform 17. Does not bind agonists but may act through oligomerization with binding-competent OPRM1 isoforms and reduce their ligand binding activity.
See full target information OPRM1

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com